公开(公告)号：US20090270330A1

公开(公告)日：2009-10-29

申请号：US12497148

申请日：2009-07-02

申请人： Sudershan Kumar ARORA ,  Vandita Srivastava ,  Sameer Shankar Walunj

发明人： Sudershan Kumar ARORA ,  Vandita Srivastava ,  Sameer Shankar Walunj

IPC分类号： A61K38/16 ,  A61P17/06

CPC分类号： A61K36/66 ,  Y02A50/39

摘要： A purified Arabinogalactan-Protein (AGP) composition isolated through a selective method from the leaves and/or stems of Argemone mexicana plant is described. Also described is a purified Arabinogalactan-Protein (AGP) composition isolated from the leaves and/or stems of Argemone mexicana plant, which has one or more of the following effects: immunosuppression, lymphoproliferation inhibition, cytokine modulation such as IL-2 inhibition, IFN-γ inhibition, or IL-10 induction; keratinocyte proliferation inhibition, keratolytic activity and inhibitory activity in Mouse Ear Swelling test (MEST).

摘要翻译： 描述了通过选择性方法从Argemone mexicana植物的叶和/或茎分离的纯化的阿拉伯半乳聚糖蛋白（AGP）组合物。 还描述了从茄科植物的叶子和/或茎分离的纯化的阿拉伯半乳聚糖蛋白（AGP）组合物，其具有以下一种或多种作用：免疫抑制，淋巴增殖抑制，细胞因子调节如IL-2抑制，IFN γ抑制或IL-10诱导; 角质形成细胞增殖抑制，角质溶解活性和小鼠耳肿胀试验（MEST）中的抑制活性。

公开(公告)号：US20080227836A1

公开(公告)日：2008-09-18

申请号：US12092009

申请日：2006-10-26

申请人： Makarand Krishnakumar Avachat ,  Nikhil Prabhakar Malewar ,  Umesh Nandkumar Khatavkar

发明人： Makarand Krishnakumar Avachat ,  Nikhil Prabhakar Malewar ,  Umesh Nandkumar Khatavkar

IPC分类号： A61K31/41 ,  A61P9/00

CPC分类号： A61K9/2054 ,  A61K9/2009 ,  A61K9/2027 ,  A61K9/2866 ,  A61K31/41

摘要： A stable solid oral dosage form comprising valsartan or a pharmaceutically acceptable salt thereof and pharmaceutically acceptable additives such as sugar (derivatives) and cellulose (derivatives). The active agent is present in an amount less than 35% by weight based on the total weight of the solid oral dosage form. Disclosed is also a process of forming a valsartan-containing composition; which process comprises blending valsartan with pharmaceutically acceptable additives, dry compressing, milling and screening said mixture to obtain granules. Said granules are compressed into tablets and are subsequently coated.

摘要翻译： 包含缬沙坦或其药学上可接受的盐和药学上可接受的添加剂如糖（衍生物）和纤维素（衍生物）的稳定的固体口服剂型。 基于固体口服剂型的总重量，活性剂的存在量小于35重量％。 还公开了形成含缬沙坦的组合物的方法; 该方法包括将缬沙坦与药学上可接受的添加剂混合，干压缩，研磨和筛选所述混合物以获得颗粒。 将所述颗粒压制成片剂并随后涂覆。

公开(公告)号：US20140171401A1

公开(公告)日：2014-06-19

申请号：US14187724

申请日：2014-02-24

申请人： LUPIN LTD.

发明人： Sanjay WAGH ,  Hidaytulla AGA ,  Makarand AVACHAT ,  Himadri SEN

IPC分类号： A61K31/546

CPC分类号： A61K31/546 ,  A61K9/0056

摘要： A chewable tablet comprising Cefixime having a mean particle size between 20μ and 120μ wherein the said composition demonstrates bioequivalence to a suspension of Cefixime trihydrate. The process of preparation of the chewable tablet comprises the steps of optionally micronizing Cefixime such that the mean particle size of the Cefixime particles is between 20μ and 120μ, blending with other excipients, roll compaction, milling to form granules, blending to form a secondary blend and compression of the secondary blend to form tablets.

摘要翻译： 一种咀嚼片，其包含平均粒径在20μ和120μ之间的头孢克肟，其中所述组合物显示与头孢克肟三水合物的悬浮液的生物等效性。 咀嚼片的制备方法包括以下步骤：任选地将头孢克肟微粉化，使得头孢克肟颗粒的平均粒径为20-120μ，与其它赋形剂混合，辊压，研磨形成颗粒，共混以形成二次共混物 并压制二次共混物以形成片剂。

公开(公告)号：US20090022809A1

公开(公告)日：2009-01-22

申请号：US12095767

申请日：2005-12-02

申请人： Sachin Pundlik Kolhe ,  Subrata Kundu ,  Sanjay Chhagan Wagh ,  Makarand Krishnakumar Avachat ,  Himadri Sen

发明人： Sachin Pundlik Kolhe ,  Subrata Kundu ,  Sanjay Chhagan Wagh ,  Makarand Krishnakumar Avachat ,  Himadri Sen

IPC分类号： A61K9/16

CPC分类号： A61K31/00 ,  A61K9/1635 ,  A61K9/2886

摘要： A stable taste masked, pharmaceutical composition comprising a plurality of coated, non-disintegrating discrete dosage units, said units comprising of a core comprising one or more cephalosporins such as cefuroxime axetil and cefpodoxime proxetil and one or more coating layers. Cefuroxime axetil is in α-crystalline and amorphous forms, where at least 30% of the Cefuroxime axetil is in the α-crystalline form, wherein the particle size distribution of the α-crystalline form being such that 100% of the particles have a particle size below 250μ. The ratio of the crystalline fraction to the amorphous fraction ranges from 0.3:0.7 to 0.99:0.01. The particle size of cefpodoxime proxetil is such that 90% of the particles are below 15μ. The process of preparation of coated, non-disintegrating pellets comprising the steps of reducing the particle size of the one or more cephalosporins, blending with the other excipients, wet granulation, extrusion, spheronization, drying and screening to obtain pellets, said pellets being further coated with one or more layers of film coating to achieve taste masking.

摘要翻译： 稳定的掩味的药物组合物，其包含多个涂覆的，不分散的离散剂量单位，所述单元由包含一种或多种头孢菌素如头孢呋辛酯和头孢泊肟酯的核心和一个或多个涂层组成。 头孢呋辛酯是α-晶型和无定形形式，其中至少30％的头孢呋辛酯为α-晶型，其中α-晶形的粒度分布使得100％的颗粒具有颗粒 尺寸在250mu以下。 结晶部分与无定形部分的比例为0.3:0.7至0.99:0.01。 头孢泊肟酯的粒径使得90％的颗粒小于15mu。 包衣，非崩解丸剂的制备方法包括以下步骤：减少一种或多种头孢菌素的粒度，与其它赋形剂混合，湿法制粒，挤出，滚圆，干燥和筛选以获得丸粒，所述丸粒进一步 涂覆一层或多层薄膜包衣以达到掩味。

公开(公告)号：US20070292500A1

公开(公告)日：2007-12-20

申请号：US11597460

申请日：2004-05-21

申请人： Sanjay Wagh ,  Hidaytulla Aga ,  Himadri Sen

发明人： Sanjay Wagh ,  Hidaytulla Aga ,  Himadri Sen

IPC分类号： A61K9/62 ,  A61K31/133 ,  A61K9/64 ,  A61P25/24 ,  A61K9/48

CPC分类号： A61K9/4808 ,  A61K9/2027 ,  A61K9/2813 ,  A61K9/282 ,  A61K9/284

摘要： Extended release pharmaceutical composition of Venlafaxine hydrochloride comprising a pharmaceutically acceptable capsule containing minitablets. The minitablets comprise from about 20% to about 70% by weight effective amount of Venlafaxine hydrochloride, polyvinyl acetate, one or more pharmaceutically acceptable excipients. The minitablets have diameter from about 1 mm to 5 mm and are coated with a release controlling composition.

摘要翻译： 盐酸文拉法辛的延长释放药物组合物，其包含含有微型药物的药学上可接受的胶囊。 微型药物包含约20％至约70％的有效量的盐酸文拉法辛，聚乙酸乙烯酯，一种或多种药学上可接受的赋形剂。 微型药筒具有约1mm至5mm的直径，并涂覆有释放控制组合物。

公开(公告)号：US20070286901A1

公开(公告)日：2007-12-13

申请号：US11579988

申请日：2004-05-10

申请人： Sanjay Wagh ,  Hidaytulla Aga ,  Makarand Avachat ,  Himadri Sen

发明人： Sanjay Wagh ,  Hidaytulla Aga ,  Makarand Avachat ,  Himadri Sen

IPC分类号： A61K9/20 ,  A61K31/545 ,  A61P31/04

CPC分类号： A61K31/546 ,  A61K9/0056

摘要： A chewable tablet comprising Cefixime having a mean particle size between 20 μ and 120 μ wherein the said composition demonstrates bioequivalence to a suspension of Cefixime trihydrate. The process of preparation of the chewable tablet comprises the steps of optionally micronizing Cefixime such that the mean particle size of the Cefixime particles is between 20 μ and 120 μ, blending with other excipients, roll compaction, milling to form granules, blending to form a secondary blend and compression of the secondary blend to form tablets.

摘要翻译： 一种包含Cefixime的咀嚼片，其平均粒度为20-120微米，其中所述组合物显示出Cefixime三水合物的悬浮液的生物等效性。 咀嚼片的制备方法包括以下步骤：任选地将头孢克肟微粉化，使得头孢克肟颗粒的平均粒度为20-120微米，与其它赋形剂混合，辊压，研磨形成颗粒，混合形成 二次混合和二次混合物的压缩以形成片剂。

公开(公告)号：US20060229438A1

公开(公告)日：2006-10-12

申请号：US10527834

申请日：2002-09-20

申请人： Valakunja Nagaraja ,  Uijini Havaldar ,  Bhairab Nath

发明人： Valakunja Nagaraja ,  Uijini Havaldar ,  Bhairab Nath

IPC分类号： A61K39/40 ,  C12P21/06 ,  C12N5/06 ,  C07K16/12

CPC分类号： C07K16/1289 ,  C07K16/40 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/622

摘要： The present invention relates to the development of monoclonal antibodies that specifically inhibit DNA gyrase from M. tuberculosis. M. smegmaris and possibly from other related bacterial species. More particularly, it has been shown that the inhibition of the enzyme is by a hitherto unknown and novel mechanism. The present invention also relates to a DNA sequence of single chain antibody consisting of complementarity determining regions of mAb. The monoclonal antibody, single chain antibody and peptides derived thereof could be useful for developing lead molecules for tuberculosis therapy. The antibodies and derived materials could be useful for a variety of purposes, including diagnosis of mycobacterial infections. The present invention also relates to the modification of antibodies and derived materials for use against diverse microbial infections and other potential applications derived thereof.

摘要翻译： 本发明涉及特异性抑制结核分枝杆菌DNA促旋酶的单克隆抗体的开发。 M. smegmaris，可能来自其他相关的细菌物种。 更具体地，已经表明，酶的抑制是迄今未知的和新颖的机制。 本发明还涉及由mAb的互补决定区组成的单链抗体的DNA序列。 单克隆抗体，单链抗体及其衍生的肽可用于开发用于结核病治疗的铅分子。 抗体和衍生的材料可用于各种目的，包括诊断分枝杆菌感染。 本发明还涉及针对多种微生物感染和其衍生的其它潜在应用的抗体和衍生材料的修饰。

公开(公告)号：US20050245738A1

公开(公告)日：2005-11-03

申请号：US10838431

申请日：2004-05-03

申请人： Girij Singh ,  Himadri Sen ,  Dhananjai Srivastava ,  Himanshu Godbole ,  Gurvinder Singh ,  Pravin Mahajan ,  Umesh Rananaware ,  Sagar Nehate ,  Sanjay Wagh

发明人： Girij Singh ,  Himadri Sen ,  Dhananjai Srivastava ,  Himanshu Godbole ,  Gurvinder Singh ,  Pravin Mahajan ,  Umesh Rananaware ,  Sagar Nehate ,  Sanjay Wagh

IPC分类号： A61K31/545 ,  C07D501/00 ,  C07D501/18

CPC分类号： C07D501/00

摘要： The present invention relates to a stable and bioavailable crystalline form of a third generation cephalosporin antibiotic, cefdinir and a process for the preparation thereof. The present invention also relates to a pharmaceutical composition containing the novel crystalline cefdinir, useful in the treatment of maladies such as bacterial infections.

摘要翻译： 本发明涉及第三代头孢菌素抗生素，头孢地尼的稳定和生物可利用的结晶形式及其制备方法。 本发明还涉及含有新型结晶头孢地尼的药物组合物，其可用于治疗诸如细菌感染的疾病。